Cost-effectiveness of nivolumab vs. ipilimumab/nivolumab vs. trifluridine/tipiracil or mFOLFOX6/cetuximab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.

被引：0
|
作者：
Chu, Jacqueline N.
Choi, Jin G.
Ostvar, Sassan
Torchia, James Anthony
Reynolds, Kerry Lynn
Gainor, Justin F.
Chung, Daniel C.
Clark, Jeffrey W.
Hur, Chin
机构：
[1] Massachusetts Gen Hosp, Boston, MA USA
[2] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA USA
[3] Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e15134
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15134
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Nivolumab versus nivolumab with ipilimumab versus trifluridine/tipiracil for metastatic microsatellite instability-high colorectal cancer: A modeling decision analysis
    Chu, Jacqueline N.
    Choi, Jin G.
    Ostvar, Sassan
    Torchia, James A.
    Reynolds, Kerry Lynn
    Gainor, Justin F.
    Chung, Daniel C.
    Clark, Jeffrey W.
    Hur, Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [2] Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
    Overman, Michael J.
    Lonardi, Sara
    Wong, Ka Yeung Mark
    Lenz, Heinz-Josef
    Gelsomino, Fabio
    Aglietta, Massimo
    Morse, Michael A.
    Van Cutsem, Eric
    McDermott, Ray
    Hill, Andrew
    Sawyer, Michael B.
    Hendlisz, Alain
    Neyns, Bart
    Svrcek, Magali
    Moss, Rebecca A.
    Ledeine, Jean-Marie
    Cao, Z. Alexander
    Kamble, Shital
    Kopetz, Scott
    Andre, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (08) : 773 - +
  • [3] Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer
    Chu, Jacqueline N.
    Choi, Jin
    Ostvar, Sassan
    Torchia, James A.
    Reynolds, Kerry Lynn
    Tramontano, Angela
    Gainor, Justin F.
    Chung, Daniel C.
    Clark, Jeffrey W.
    Hur, Chin
    CANCER, 2019, 125 (02) : 278 - 289
  • [4] Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer
    Morse, Michael A.
    Overman, Michael J.
    Hartman, Leighanne
    Khoukaz, Taline
    Brutcher, Edith
    Lenz, Heinz-Josef
    Atasoy, Ajlan
    Shangguan, Tong
    Zhao, Huanyu
    El-Rayes, Bassel
    ONCOLOGIST, 2019, 24 (11): : 1453 - 1461
  • [5] Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer
    Liu, Tong
    Liu, Shuang
    Guan, Shangwei
    Tai, Yu
    Jin, Yao
    Dong, Mei
    JOURNAL OF CHEMOTHERAPY, 2023, 35 (08) : 745 - 752
  • [6] RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study
    Cohen, Romain
    Bennouna, Jaafar
    Meurisse, Aurelia
    Tournigand, Christophe
    De La Fouchardiere, Christelle
    Tougeron, David
    Borg, Christophe
    Mazard, Thibault
    Chibaudel, Benoist
    Garcia-Larnicol, Marie-Line
    Svrcek, Magali
    Vernerey, Dewi
    Menu, Yves
    Andre, Thierry
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [7] A pathological complete response after nivolumab plus ipilimumab therapy for DNA mismatch repair-deficient/microsatellite instability-high metastatic colon cancer: A case report
    Igaue, Shota
    Okuno, Takayuki
    Ishibashi, Hajime
    Nemoto, Masaru
    Hiyoshi, Masaya
    Kawasaki, Hiroshi
    Saitoh, Hitoaki
    Saitoh, Makoto
    Akagi, Kiwamu
    Yamamoto, Junji
    ONCOLOGY LETTERS, 2022, 24 (01)
  • [8] Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer: A Preliminary Report of Case Series
    Pan, Tao
    Yang, Hui
    Wang, Wu-yi
    Rui, Yuan-yi
    Deng, Zi-jian
    Chen, Yung-chang
    Liu, Chao
    Hu, Hai
    CLINICAL COLORECTAL CANCER, 2024, 23 (01) : 104 - 110
  • [9] First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
    Lenz, Heinz-Josef
    Van Cutsem, Eric
    Limon, Maria Luisa
    Wong, Ka Yeung Mark
    Hendlisz, Alain
    Aglietta, Massimo
    Garcia-Alfonso, Pilar
    Neyns, Bart
    Luppi, Gabriele
    Cardin, Dana B.
    Dragovich, Tomislav
    Shah, Usman
    Abdullaev, Sandzhar
    Gricar, Joseph
    Ledeine, Jean-Marie
    Overman, Michael James
    Lonardi, Sara
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (02) : 161 - +
  • [10] Microbiome analyses in patients with previously treated, deficient DNA mismatch repair/microsatellite instability-high metastatic colorectal cancer treated with nivolumab ± ipilimumab: CheckMate 142
    Kopetz, Scott
    Zagonel, Vittorina
    Overman, Michael J.
    McDermott, Ray
    Morse, Michael A.
    Chen, Franklin L.
    Lee, James
    Moss, Rebecca A.
    Ling, Lilan
    Greenfield, Alexander
    Greenawalt, Danielle
    Cao, Z. Alexander
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
12345